In the Lab Andrew Joseph Study: Rare genetic mutation appears to have protected second person from early Alzheimer’s
Health Kay Lazar — Boston Globe STAT Plus: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
In the Lab Jonathan Wosen Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say
Biotech Damian Garde STAT Plus: For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
Biotech Matthew Herper and Adam Feuerstein STAT Plus: Eli Lilly’s Alzheimer’s therapy slowed patients’ rate of cognitive decline, data show
Biotech Adam Feuerstein and Damian Garde STAT Plus: What to know about the upcoming readout of Eli Lilly’s experimental Alzheimer’s therapy
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal
Politics John Wilkerson STAT Plus: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs
In the Lab Usha Lee McFarling In the whitewashed world of Alzheimer’s research, one scientist is on a quest to understand the diversity of brains
Politics Sarah Owermohle STAT Plus: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
Health Jonathan Wosen Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients
Pharmalot Ed Silverman STAT Plus: Veterans Health Administration will cover the newest Alzheimer’s drug
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
First Opinion Steven G. Smith An intimate look at dementia — and the emotional toll it takes on family and caregivers
Biotech Adam Feuerstein and Damian Garde STAT Plus: FDA’s Billy Dunn, key figure in approval of Aduhelm, to leave agency
Politics Rachel Cohrs STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs
Biotech Adam Feuerstein STAT Plus: Eisai reports first U.S. sales of newly approved treatment for Alzheimer’s disease
The Readout LOUD Adam Feuerstein and Meg Tirrell Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection
Adam's Take Adam Feuerstein STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
Biotech Adam Feuerstein STAT Plus: FDA rejects Lilly’s bid for accelerated approval for its Alzheimer’s drug
Biotech Jason Mast STAT Plus: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
Pharmalot Ed Silverman STAT Plus: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug
Biotech Adam Feuerstein STAT Plus: FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants
Biotech Jason Mast STAT Plus: As FDA considers new Alzheimer’s drug, a case study details safety concerns